Inflexor Ventures Leads ₹65 Crore Pre-Series B in Butterfly Learnings to Scale Pediatric Neurodevelopmental Care Across India

The round also saw participation from existing investors Enzia Ventures, Insitor Impact Asia Fund, and IIMA Ventures

Butterfly Learnings, India's first full-stack paediatric behavioural health platform for neurodivergent children, has raised INR 65 Crore in its Pre - Series B funding round, led by Inflexor Ventures, with continued participation from existing investors Insitor Partners and Enzia Ventures, reaffirming their conviction in the company's long-term growth. The fresh capital will be used to expand Butterfly's centre network across India, strengthen its technology platform, and commercialize its breakthrough early autism screening solution.

The funding comes at a time when India is witnessing growing awareness around neurodevelopmental disorders, while access to structured and evidence-based care continues to remain limited. Nearly 45 million children across the country are estimated to live with conditions such as Autism Spectrum Disorder (ASD), ADHD and learning disabilities, yet only a small percentage receive timely intervention. Delayed diagnosis, fragmented care pathways and a shortage of trained specialists continue to prevent children from receiving support during the most critical years of brain development.

Founded by Dr. Sonam Kothari, a paediatric neurologist and one of the few clinicians in India who is also a US Board-Certified Behaviour Analyst, and Dr. Abhishek Sen, a serial healthcare entrepreneur who previously built and exited medtech startup Biosense Technologies, Butterfly Learnings was established to address this systemic gap through an integrated model of care. The company combines clinical therapy, inclusive schooling, digital therapeutics, diagnostics, and technology-enabled interventions under a single platform, creating a seamless care journey for neurodivergent children and their families.

Today, Butterfly Learnings operates 90+ centres across more than 22 cities, making it one of India's largest providers of neurodevelopmental care. Butterfly Learnings is the only BHCOE (Behavioural Health Center of Excellence) accredited therapist training institute in Asia, reflecting its commitment to globally recognised standards of behavioural healthcare delivery.

A key differentiator for Butterfly Learnings is Get SET Early, a patented eye-tracking autism screening technology for which the company holds an exclusive global licence. Following CDSCO approval, the solution enables autism screening in children as young as one year old, helping reduce diagnostic delays and enabling earlier intervention.

The newly raised capital will support Butterfly Learnings' expansion from being predominantly focused on Maharashtra to other geographies in India, strengthen its digital and AI capabilities, scale the deployment of Get SET Early through hospitals and pediatricians, and expand its in-house therapist training programme.

Commenting on the fundraise, Dr. Sonam Kothari, CEO & Co-founder, Butterfly Learnings, said, "When we started Butterfly Learnings, the question we kept coming back to was not whether families wanted help; they desperately did, but why the system kept failing them. The answer was always the same: fragmentation. A child gets diagnosed in one place, receives therapy in another, and attends a school that has no idea what either of those two places recommended. No one is accountable for the whole journey. Butterfly was built to own that whole journey, with standardised protocols, rigorous clinical data, and a platform that uses technology to deliver evidence-based outcomes for every child, guided by empathy and transparency at every step. This investment means we can take that model, and those outcomes, to many more children who deserve the same chance."

Explaining the rationale behind the investment, Pratip Mazumdar, Partner, Inflexor Ventures, said, "Butterfly is an investment we have made from our Fund III in the specialty healthcare domain. Dr. Sonam Kothari brings clinical depth alongside operating business experience that is genuinely rare; and Dr. Abhishek Sen brings the execution capability that turns clinical insight into a scalable business. Together, they have built a platform that is already demonstrating what it means to deliver standardized, outcome-tracked care for neurodivergent children at scale. The data moat they are accumulating, anchored by the Get SET Early biomarker, makes this a platform that becomes more defensible with every child it serves."

Looking ahead, Butterfly Learnings plans to deepen its presence across India, strengthen partnerships with hospitals and paediatricians, expand access to inclusive education, advance AI-enabled precision care, reinforcing its mission of making high-quality neurodevelopmental care accessible to families across India.

About Butterfly Learnings

Butterfly Learnings (Bombay Autism Services Private Limited) is India's first full-stack paediatric behavioural health platform focused on delivering integrated care for neurodivergent children. Founded by Dr. Sonam Kothari and Dr. Abhishek Sen, the company brings together clinical therapy, inclusive schooling, digital therapeutics, diagnostics, and technology-enabled interventions to support children with Autism Spectrum Disorder (ASD), ADHD, and other neurodevelopmental conditions. Butterfly Learnings operates 90+ centres across more than 22 cities in India and is committed to making evidence-based, high-quality neurodevelopmental care more accessible to families across the country.

For more information, visit www.butterflylearnings.com.

About Inflexor Ventures

Co-founded by Venkat Vallabhaneni, Jatin Desai and Pratip Mazumdar, Inflexor is a sector-agnostic Venture Capital firm managing INR 1300 crore of AUM and investing in technology-based early stage companies with a portfolio of 27 companies. Inflexor has been an early investor in startups like Atomberg, Kale Logistics, PlayShifu, Entropik, Bellatrix, Clickpost and Cloudsek. The team at Inflexor brings decades of experience in fund management and investments, serial entrepreneurship with exits to US-listed companies, and global technology and operational roles.

For more information, Visit www.inflexor.vc
###

4baseCare Launches Targt Indiegene® V2, Bringing A Biology-First Approach to Comprehensive Cancer Profiling

• Five years after the launch of Indiegene V1, the next generation expands to 2,206 genes with most comprehensive coverage of Hallmarks of Cancer, HRD scoring and 36 HRR genes profiling, and 299 fusions, individualised Tumour Mutation Burden (iTMB) score with percentile scoring

4baseCare, a precision oncology company building genomic and clinical intelligence for diverse populations, today announced the launch of TARGT Indiegene® V2, the next generation of its comprehensive genomic profiling (CGP) test for cancer biomarker testing.

The journey began on 15 August 2021, when 4baseCare launched the first Indiegene developed from insights generated through Indian tumour genomics and with the ambition of making comprehensive cancer profiling more accessible. Five years of continuous innovation, clinical experience and genomic insights have now led to Indiegene V2.

With 2,206 genes, V2 significantly expands the genomic breadth of the original panel. More importantly, it introduces a different way of looking at cancer.

Cancer is more than a mutation. Tumours are driven by interconnected biological processes that influence growth, survival, DNA repair, immune evasion and progression. TARGT Indiegene® V2 brings this perspective into CGP through genomic coverage mapped across the Hallmarks of Cancer.

Key capabilities include:

• 2,206 genes for broad genomic profiling
• Hallmarks of Cancer-led coverage to understand the biology driving tumour behaviour
• Immunotherapy biomarkers like MSI and individualised Tumour Mutation Burden (iTMB) score with percentile scoring. 
• HRD scoring and comprehensive coverage of 36 HRR genes. 
• CNVs and 299 clinically relevant fusions, among the most extensive fusion coverage available in commercial CGP assays

“Indiegene V2 is not simply a larger gene panel. It represents a shift from looking for individual biomarkers to understanding the biology behind cancer. As we take Indiegene to more patients and clinicians across global markets, our ambition remains the same, which is to make comprehensive, meaningful precision oncology accessible across diverse populations.” said Hitesh Goswami, Co-founder & CEO, 4baseCare

“Developed through 4baseCare’s experience in population-relevant oncology and now being taken to global markets, TARGT Indiegene® V2 represents the next chapter in our vision to build globally relevant precision-oncology solutions for diverse and historically underrepresented populations”, Kshitij Rishi, Co-Founder and COO, 4baseCare

About 4baseCare

Backed by Infosys and Illumina, 4baseCare is a precision oncology company working to make personalised cancer care more accessible, inclusive and data-driven. The company combines advanced genomic testing, population-relevant clinico-genomic datasets, real-world evidence and AI-powered analytics to support more informed cancer-care decisions. Headquartered in Bengaluru, 4baseCare is expanding its precision oncology footprint across India and international markets with advanced genomics labs in Dubai, Nepal and Philippines. 4baseCare OncoTwin, an AI-based Oncology Digital Twin platform was recently selected for MSKCC iHub program.

Tata Elxsi and OpenAna Unveil Anatel™, An AI‑Native Platform Redefining Regulatory‑Ready MedTech Software Engineering

Tata Elxsi and OpenAna have jointly launched AnaTel™, an AI‑native software engineering platform for healthcare and MedTech, designed to streamline regulatory compliance and accelerate SaMD development cycles by up to 60%. The debut at DeviceTalks Boston 2026 marks a significant milestone in AI‑driven, regulatory‑ready software delivery for medical technology.

AnaTel™ embeds autonomous AI agents directly into the engineering workflow. Unlike developer productivity tools that focus on code generation alone, AnaTel™ operates across the full AI-Driven Software Delivery Lifecycle, from requirements and architecture through deployment, verification and validation, and continuous optimization, making it a true end-to-end engineering execution platform for regulated environments.

AnaTel™ functions as a configurable AI software team, producing code, documentation, test cases, and compliance artifacts through a specialized Healthcare and Life Sciences agent tailored for MedTech regulatory and engineering demands.

Human engineers and regulatory specialists maintain oversight at every critical review and decision stage. AnaTel™ integrates eSTAR‑aligned submission preparation, requirements traceability matrices, verification and validation records, and audit‑trail documentation directly into daily engineering workflows. By embedding compliance into execution, the platform shortens SaMD (Software as a Medical Device) development and change assessment cycles from eight weeks to just 72 hours, delivering productivity gains of up to 60%.

Key Highlights of AnaTel™

• Launch Context: Introduced at DeviceTalks Boston 2026 by Tata Elxsi and OpenAna
• Purpose: End‑to‑end AI‑native platform for regulated healthcare and MedTech software engineering
• Impact: Cuts SaMD timelines from 8 weeks to 72 hours, with up to 60% productivity gains

Regulatory Drivers

• FDA Draft Guidance (2025): AI‑Enabled Device Software Functions now require lifecycle documentation, traceability, and validation evidence
• Europe’s MDCG 2025‑26: Similar emphasis on rigorous documentation and compliance
• Challenge: Manual assembly of requirements, test cases, and regulatory artifacts across disconnected tools. AnaTel™ embeds compliance into daily workflows, eliminating bottlenecks

Platform Capabilities

• Autonomous AI Agents: Configurable AI software teams generate code, documentation, test cases, and regulatory artifacts
• Healthcare Expert Agent: Fine‑tuned for MedTech regulatory contexts, ensuring contextualized compliance
• Workflow Coverage: Requirements → Architecture → Deployment → Verification/Validation → Continuous Optimization
• Submission Support: eSTAR‑aligned preparation, traceability matrices, audit‑trail documentation

Tata Elxsi’s Role

• Expertise: Decades of experience in regulated medical device environments
• Strengths: Design‑led, AI‑first engineering, ISO 13485 certified Healthcare & Life Sciences practice
• Contribution: Shaped AnaTel™’s reasoning around traceability, validation, and compliance

OpenAna’s Role

• Platform Innovation: Provides Ana, a multi‑agent autonomous engineering system spanning software, security, DevOps, and AI/ML
• Differentiator: Goes beyond coding assistants — full ownership of engineering workflows, with enterprise‑grade guardrails and auditable AI
• Contribution: Embedded autonomous engineering into MedTech’s demanding regulatory domain

Leadership Perspectives

• Sreevatsa Sahasranaman (Tata Elxsi): AnaTel™ accelerates regulatory‑ready engineering while keeping human experts in control
• Rajiv Sondhi (OpenAna): Autonomous AI agents act as reliable co‑engineers in regulated healthcare
• Muthusamy Selvaraj (Tata Elxsi): AnaTel™ exemplifies STEP.UP co‑innovation — accountability for outcomes, not just technology

Strategic Significance

• For Healthcare Teams: Reduces compliance burden, integrates documentation into workflows
• For Regulators: Provides transparent, auditable AI‑driven engineering evidence
• For Industry: Sets a benchmark for AI‑native platforms in regulated environments, bridging speed with safety. 

IndiaAI and ICMR Partner to Advance Ethical AI in Healthcare

IndiaAI and ICMR have signed a landmark MoU to build a nationally coherent AI ecosystem for healthcare, combining IndiaAI’s compute and dataset platforms with ICMR’s biomedical expertise. This collaboration is expected to accelerate ethical, scalable AI adoption in public health across India.

Key Highlights of the MoU

• Partnership Entities: IndiaAI (MeitY initiative via Digital India Corporation) and ICMR (India’s apex biomedical research body).
• Objective: Establish a structured framework to advance healthcare outcomes through responsible AI, ensuring interoperability and national coherence.
• Core Collaboration Pillars:
  • AIKosh Dataset Platform: ICMR will contribute anonymised, ethics-approved datasets and AI models via its MIDAS framework.
  • Compute Access: IndiaAI will provide subsidised GPU-based high-performance computing infrastructure to ICMR.
  • Collaborative AI Use Cases: Joint development of AI-powered solutions targeting priority public health challenges.

Ethical and Regulatory Context

• ICMR Guidelines: Ethical Guidelines for AI in Biomedical Research and Healthcare (2023) ensure accountability, privacy, and fairness.
• Global Recognition: IndiaAI and ICMR’s NIRDHDS recognised as Pioneer Countries under the HealthAI Global Regulatory Network in 2025.

Strategic Significance

Dimension	Impact
National Impact	Bridges AI infrastructure with biomedical research to catalyse innovation in diagnostics and treatment.
Global Positioning	Positions India as a leader in responsible AI governance for healthcare.
Innovation Catalyst	Provides startups and researchers access to datasets and compute resources, reducing barriers to entry.

Outlook

This MoU is expected to accelerate AI-driven healthcare innovation in India, while safeguarding patient rights and data privacy. It builds on prior collaborations and global recognition, marking India’s intent to lead in ethical AI governance for healthcare.

Medtronic Launches Adaptive DBS in India: Real‑Time Therapy for Parkinson’s Patients

Medtronic, a global leader in healthcare technology, today announced the launch of its Adaptive Deep Brain Stimulation (aDBS) system, an innovation over conventional DBS, in India to further improve quality of life of patients living with Parkinson’s disease.

The prevalence of Parkinson's disease (PD) in India is roughly 10% of the global burden, which is a considerable public health concern. 

Parkinson’s is a progressive neurological condition that can affect how a person moves and functions in everyday life. Over time, it may make routine activities such as walking, writing, or holding everyday objects more difficult. While movement-related challenges are often the most visible, the condition can also influence other aspects of daily living, including communication, sleep, and overall well‑being. Today, a range of treatment approaches help manage symptoms as the disease evolves. Care is typically tailored over time, with treatment pathways adjusted based on individual needs and clinical assessment by specialists.

Treatment options like Deep Brain Stimulation exist which involve manual adjustment of stimulation levels throughout the day, usually managed by patients or caregivers. Medtronic’s aDBS technology is designed to adapt real time to changes in a patient’s condition or medication needs—helping deliver more consistent symptom management. The aDBS system uses BrainSense™ technology, which has been approved by the U.S. Food and Drug Administration (FDA).

Adaptive deep brain stimulation (aDBS) is designed to automatically adjust therapy based on changes in brain signals or patient activity. By responding in real time, it aims to provide more consistent symptom control, minimize side effects, and help extend the life of the implanted device’s battery.

With India expected to witness a significant rise in Parkinson’s disease cases—projected to become the second-highest globally within the next five years7—the introduction of the aDBS system comes at a critical time. Although there is currently no cure for conditions such as Parkinson’s disease, deep brain stimulation (DBS) has been transforming the lives of patients with Parkinson’s and other neurological disorders for more than three decades. 

DBS uses a small, pacemaker-like device, placed under the skin of the chest, to send electronic signals to an area in the brain that controls movement. To give you relief, these signals block some of the brain messages that cause the movement symptoms of Parkinson’s.

On the occasion, Prateek Tiwari, Senior Director, Neuroscience & Specialty therapies, Medtronic India said, “We are extremely proud to introduce this advanced technology in India, where Parkinson’s disease is an increasingly significant healthcare concern. Our mission has always been to alleviate pain, restore health, and extend life, and the introduction of this system reflects our continued commitment to that mission. This milestone not only reaffirms our dedication to addressing the growing burden of Parkinson’s disease but also strengthens our leadership in bringing cutting-edge healthcare technologies to India to ultimately improve patients’ quality of life.’’

As the burden of a disease such as Parkinson’s will rise, continued investment in cutting-edge technologies will be essential to expanding access to better care, supporting clinicians with deeper insights, and ultimately improving the quality of life for patients across the country.

Patients considering deep brain stimulation (DBS) typically begin by consulting a Movement Disorder Specialist, usually a neurologist, who evaluates whether their condition may benefit from this therapy. DBS follows a coordinated, team-based approach, with patients often referred to a comprehensive DBS clinic or neurosurgery board for further assessment. If considered suitable, a Functional Neurosurgeon—specially trained to perform the procedure—works alongside the care team to implant and program the device.

All information contained herein is for general awareness purposes only, and nothing contained herein should be construed as medical advice or recommendation. Patients should consult their physician to discuss their conditions and seek relevant medical advice.

About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

India’s Poshan Tracker Wins Global Recognition as a Digital Nutrition Governance Model

India’s fight against malnutrition has entered a new era with the Poshan Tracker, a digital platform that combines technology, transparency, and community engagement to transform nutrition governance. Launched on 1 March 2021, the application has become the backbone of POSHAN Abhiyaan, enabling real‑time monitoring of Anganwadi services and ensuring benefits reach those who need them most.

A Digital Leap in Nutrition Governance

• The Poshan Tracker monitors pregnant women, lactating mothers, children up to six years, and adolescent girls.
• As of March 2026, it covers nearly 14 lakh Anganwadi Centres and tracks over 8.95 crore beneficiaries.
• The platform has earned the Prime Minister’s Award for Excellence in Public Administration (2024).

Advanced Identity Verification and Transparency

• Facial Recognition System (FRS)Aadhaar‑based tracking prevent leakages and eliminate ghost entries.
• Digital integration has improved operational efficiency, ensuring timely delivery of supplementary nutrition and related services.

Accessible Support for Citizens

• The Poshan Helpline (1515), active since November 2025, allows beneficiaries to raise concerns in 17 languages.
• This grievance redressal system strengthens accountability and builds trust between communities and service providers.

Nutrition as a Jan Andolan

• Campaigns like Poshan Maah (September) and Poshan Pakhwada (April) mobilize communities nationwide.
• Activities include home visits, growth monitoring drives, health camps, street plays, and convergence events.
• The focus is on behavioural change—promoting infant feeding practices, dietary diversity, hygiene, and healthy lifestyles.

Poshan Pakhwada 2026: Maximizing Brain Development

Theme: Maximizing Brain Development in the First Six Years of Life

• Mother and child nutrition
• Early stimulation for brain growth
• Play‑based education in early years
• Reducing screen time for children
• Strengthening Anganwadi centres with community support

Scientific evidence shows that 85% of brain development occurs before age six, making early nutrition and stimulation critical.

Rashtriya Poshan Maah

• Celebrated every September to reinforce nutrition awareness across villages, schools, health facilities, and Anganwadi centres.
• The 2025 edition focused on maternal nutrition, infant feeding, ECCE, and reducing sugar and oil consumption to fight obesity.

Building Human Capital for Viksit Bharat

• Mission Poshan 2.0 emphasizes convergence across health, education, and community sectors.
• Technology‑enabled governance ensures efficiency and transparency.
• Community participation drives sustained behavioural change.

Improved nutrition strengthens human capital, leading to better health, learning outcomes, and productivity. As India advances towards Viksit Bharat 2047, investments in nutrition and early childhood development remain central to building a healthy, resilient population.

From Lungs to Hearts: How Digital Twins Are Revolutionizing Indian Healthcare

Digital twin technology—virtual replicas of organs or entire patient systems—is rapidly emerging as a game‑changer in India’s healthcare ecosystem. By integrating AI, imaging, and real‑time patient data, digital twins enable predictive diagnostics, personalized treatment, and advanced surgical planning.

What is a Digital Twin in Healthcare?

• A digital twin is a virtual model of a patient’s body or organ, created using CT scans, vitals, lab reports, and wearable data.
• Doctors can simulate disease progression, predict treatment responses, and plan interventions with greater accuracy.
• It combines AI, IoT, big data, and imaging workflows for real‑time monitoring and diagnostics.

Key Digital Twin Breakthroughs in India

Respiratory Diagnostics – LTTS AI Lung Digital Twin

• Launch: March 2026, San Jose (by L&T Technology Services).
• Powered by: NVIDIA AI infrastructure.
• Applications: Lung cancer, COPD, infectious diseases.
• Features: Immersive 3D visualization, CT imaging workflows, AI‑driven surgical navigation.
• Significance: First India‑origin MedTech platform with global deployment.

Cardiac Care – Apollo Hospitals

• Use Case: Digital twin simulations of the human heart.
• Purpose: Optimize surgical planning, stent placement, and arrhythmia monitoring.
• Impact: Enables safer, more precise interventions in cardiovascular care.

Oncology – Predible Health & Telerad Tech

• Focus: Tumor modeling and radiotherapy planning.
• Technology: AI‑driven imaging combined with digital twin simulations.
• Benefit: Personalized cancer treatment pathways and reduced radiation risks.

Orthopedics & Prosthetics – IISc Bengaluru

• Research Area: Biomechanical digital twins for orthopedic implants and rehabilitation.
• Goal: Simulate patient‑specific bone and joint mechanics.
• Outcome: Improves implant design and recovery planning.

Personalized Medicine – Datta Meghe Institute (Wardha)

• Project: AI‑driven digital twins for predictive medicine.
• Approach: Integrates patient vitals, imaging, and lifestyle data.
• Potential: Tailored therapies and preventive care models.

Why These Are Breakthroughs

Domain	Breakthrough Example	Impact
Respiratory Care	LTTS AI Lung Digital Twin	Global MedTech leadership, advanced diagnostics
Cardiology	Apollo Hospitals	Precision surgical planning
Oncology	Predible Health, Telerad Tech	Personalized radiotherapy
Orthopedics	IISc Bengaluru	Patient‑specific implant design
Personalized Care	Datta Meghe Institute	Predictive medicine pathways

Challenges Ahead

• Clinical Validation: Large‑scale trials needed for accuracy.
• Data Privacy: Compliance with HIPAA/GDPR critical.
• Infrastructure Gaps: Many hospitals lack AI‑ready imaging systems.
• Regulatory Approvals: FDA/CE certifications required for global adoption.

India’s digital twin breakthroughs are shaping a new era of precision healthcare, with respiratory, cardiac, oncology, and orthopedic applications already underway. These innovations position India as a rising MedTech hub, but scaling will depend on policy support, infrastructure investment, and clinician training.

Benefits for Diagnostics

• Personalization: Tailored treatment pathways for individual patients.
• Predictive Analytics: Early detection of disease progression.
• Simulation: Virtual testing of surgical or therapeutic interventions.
• Efficiency: Reduces trial‑and‑error in treatment planning.

Challenges in India

• Data Privacy: Sensitive patient data must comply with HIPAA/GDPR standards.
• Infrastructure Gaps: Many hospitals lack advanced imaging and AI integration.
• Cost Barriers: High investment in AI infrastructure and clinician training.
• Regulatory Pathways: Need for clear clinical validation and approvals.

India vs. Global Adoption

Aspect	India (Emerging)	Global (Advanced)
Infrastructure	Developing AI & imaging	Mature AI ecosystems
Clinical Trials	Limited, early stage	Extensive, multi‑center
Cost Accessibility	High barrier for hospitals	Wider adoption in developed nations
Focus Areas	Respiratory, oncology, preventive care	Cardiology, neurology, full‑body twins
Policy Support	National Digital Health Mission	Stronger regulatory frameworks

Outlook

India’s healthcare sector is embracing digital twin technology as part of its broader digital health transformation. With LTTS’s AI Lung Digital Twin, Apollo’s cardiac initiatives, IISc’s biomechanical research, and startup‑driven oncology solutions, the country is positioning itself as a future hub for AI‑driven diagnostics.

Scaling adoption will require investment in infrastructure, clinician training, and regulatory clarity, but the potential to revolutionize personalized medicine and predictive healthcare is undeniable.

India’s Healthcare AI Leap: Findability Sciences, Nath School & Kamalnayan Bajaj Hospital Sign Landmark MoU

In a significant step toward accelerating the adoption of Artificial Intelligence in healthcare, Findability Sciences Private Limited, Nath School of Business & Technology, and MMRI Kamalnayan Bajaj Hospital have entered into a tripartite Memorandum of Understanding (MoU) to collaboratively research, develop, test, and deploy AI-driven healthcare solutions.

The MoU establishes a structured framework to build and validate advanced AI applications across clinical decision support, diagnostics augmentation, predictive analytics, operational optimization, patient outcomes, and overall hospital efficiency. The collaboration brings together enterprise-grade AI expertise, academic research rigor, and real-world clinical environments to ensure solutions are practical, ethical, and scalable.

Commenting on the collaboration, Anand Mahurkar, Founder & CEO, Findability Sciences, said:

Healthcare AI must be built where decisions are made—at the intersection of data, clinicians, and real operational constraints. This collaboration allows us to design and validate AI systems that are not only technically sophisticated, but clinically meaningful, compliant, and ready to scale across India’s healthcare ecosystem.

Under the agreement, Findability Sciences will lead the overall AI architecture, model development, platforms, and governance, leveraging its proprietary methodologies and enterprise AI frameworks. Kamalnayan Bajaj Hospital will provide clinical expertise, anonymized healthcare data (in compliance with statutory and ethical norms), and access to live or simulated clinical environments for testing and validation. Nath School of Business & Technology will contribute faculty expertise, research resources, and student participation to support applied research, experimentation, and documentation.

Dr. Geoge Noel Fernandes from MMRI Kamalnayan Bajaj Hospital added: 

Hospitals generate vast amounts of clinical and operational data, yet much of its potential remains untapped. By working closely with an enterprise AI partner and an academic institution, we aim to translate data into actionable intelligence that improves patient outcomes, clinician productivity and hospital efficiency without compromising ethics or patient trust. This is a step towards more efficiency and excellence in patient service.

Representing Nath School of Business & Technology, Harsh Vardhan Jajoo, Director noted:

This MoU exemplifies applied research with purpose. Our faculty and students will engage directly with real healthcare challenges, contributing to AI solutions that are tested in real environments and grounded in rigorous research, while preparing future talent for the evolving healthcare and AI landscape.

Together, the three institutions aim to bridge the gap between AI research and real-world healthcare deployment—moving beyond pilots to solutions that can measurably improve outcomes for patients, clinicians, and hospital systems.

The collaboration also enables the publication of non-confidential academic and research outcomes, subject to intellectual property and confidentiality provisions, reinforcing India’s growing role in responsible and applied AI innovation.

With this MoU, the partners signal a shared commitment to building trustworthy, data-driven healthcare systems, where AI augments clinical judgment, enhances operational resilience, and delivers measurable value at scale.

About Findability Sciences Findability Sciences - Agentic Workflow

About Nath School of Business & Technology Nath School of Business & Technology (NSBT) | Best MBA in Aurangabad

About MMRI Kamalnayan Bajaj Hospital Kamalnayan Bajaj Hospital – The Complete Hospital

AI Meets Cardiology: Bayosthiti and Narayana Partner to Predict Heart Disease in Indian Patients

Bayosthiti AI, an innovator in AI-driven healthcare and molecular diagnostics, announced a strategic partnership with Narayana Health, one of the world's largest cardiac care networks, to develop AI models that predict cardiovascular disease in Indian patients. The collaboration leverages RNA sequencing to read the active molecular instructions in cells, combined with gen AI to identify heart disease risk earlier and more accurately than conventional methods.

The study will analyze transcriptomic data (the complete set of active cellular RNA messages) from over 12,000 participants at Narayana Institute of Cardiac Sciences in Bengaluru. Using Bayosthiti's proprietary BIRT™ technology, researchers will sequence complete RNA profiles from patient blood samples to train AI models. These models will be capable of detecting distinctive patterns of cellular activity that signal coronary artery disease (blockages in heart arteries) before traditional tests show abnormalities.

Coronary artery disease affects 65 million Indians and strikes at younger ages than in Western populations. Yet, diagnostic tools remain largely calibrated to European and American patient data, creating what clinicians call the "Data Gap." Standard risk scores miss critical patterns in South Asian biology shaped by distinct genetic backgrounds and environmental factors, leading to late-stage diagnoses when intervention options narrow.

Bayosthiti AI and Narayana Health are solving this through molecular innovation and clinical scale. Narayana performs over 60,000 cardiac procedures annually, generating rich clinical data. Bayosthiti's BIRT™ (Barcode-Integrated Reverse Transcription) technology sequences complete RNA profiles at a fraction of traditional costs by processing multiple patient samples in parallel. This breakthrough makes it economically viable to build the massive datasets required to train robust AI models tailored for Indian populations, ensuring highly accurate and individualized genetic analysis.

Current diagnostics rely on anatomical imaging or protein markers, both of which detect disease after it has physically manifested. RNA sequencing captures the dynamic instructions cells are executing in real time. By analyzing which genetic instructions are being transcribed (actively used to make proteins) and at what levels, Bayosthiti's AI can detect when biological systems shift toward disease states, potentially months or years before structural damage appears.

"Just as Google Translate learned language patterns from billions of text examples, our AI learns disease patterns from millions of RNA expressions," said Dr. Rishabh M. Shetty, Head of Business Development and Clinical Applications at Bayosthiti AI. "The transcriptome gives us a real-time readout of what the body is doing right now. Our models can spot the molecular conversation that precedes a heart attack, not just the aftermath, and can do so with the same level of accuracy and efficacy as invasive procedures or other current imaging gold standards."

The clinical credibility matters. Narayana Health's scale and reputation make it an ideal validation partner. Its leadership views AI integration as the next frontier in expanding access and improving outcomes. "AI-based technologies aren't the future of medicine. They're the present," said Dr. P.M. Uthappa, Group Chief Medical Director at Narayana Health. "This collaboration lets us move from intervention to prevention. The ability to identify high-risk patients earlier and more precisely is a clinical game-changer."

The partnership builds on Bayosthiti's momentum since establishing operations in India. The company has processed samples from over 100 collaborations globally, and this study represents a significant expansion in both scope and strategic importance.

"We've relied too long on a one-size-fits-all approach to medicine," said Kutapa Muthanna, CEO of Bayosthiti AI. "This isn't just about closing a data gap. It's about building the foundation for proactive, personalized medicine created by Indians, for Indians. When we can tell someone their heart disease risk is rising before any scan shows blockage, we transform care from reactive to preventive."

The three-phase study design allows for continuous improvement. Successfully validating these AI models would provide proof-of-concept for deploying similar approaches for other high-burden diseases in India. As the partnership progresses, findings will inform the development of a blood-based diagnostic test deployable at scale across India's healthcare system.

About Bayosthiti AI

Bayosthiti AI, a wholly-owned subsidiary of US-based Biostate AI, is India’s first AI-first healthcare company pioneering Lifetime Health Management. By integrating patented BIRT™ and other cutting-edge molecular technologies with advanced generative AI, Bayosthiti is building a foundational health-tech platform for India. This platform includes 24/7 AI Clinical Assistants and AI Scientists for patients, clinicians, and researchers, making personalized precision care a reality for all.

For more information, visit https://bayosthiti.ai/.

About Narayana Hrudayalaya

Narayana Hrudayalaya, operating under the brand name Narayana Health, is one of India’s leading private healthcare service providers. The group operates a nationwide network of hospitals with a mission to deliver high-quality, safe and technology-enabled healthcare to the broader population. Renowned globally for its expertise in Cardiac Sciences, Narayana Health has been at the forefront of heart care for over two decades, performing one of the highest volumes of cardiac procedures in the world.

As the only hospital group in India with Enterprise-level Joint Commission International (JCI) accreditation, Narayana Health upholds the highest standards of quality and patient safety across its network. Guided by its core values of Quality, Compassion, and Innovation, Narayana Health remains committed to its vision of ‘Health for all. All for Health.’

For more information, visit narayanahealth.org.

AI Designs Viruses That Kill Bacteria—A New Frontier in Synthetic Biology

In a stunning leap for synthetic biology, scientists have used artificial intelligence to design viruses that can infect and kill bacteria—ushering in a new era of programmable life forms and potentially revolutionizing medicine.

Researchers at Stanford University and the Arc Institute trained an AI model named Evo on over 2 million bacteriophage genomes. The goal? To teach the system how nature builds viruses that target bacteria. Evo didn’t just remix existing genetic material—it generated 302 entirely new viral genomes, many of which had never existed in nature.

Of those, 16 assembled into fully functional viruses that successfully infected and destroyed E. coli bacteria in lab tests. This marks the first time AI has been used to design complete, working viruses from scratch.

“We’re not just accelerating evolution—we’re directing it,” said one of the lead researchers. “This opens the door to custom-built phages that could target antibiotic-resistant bacteria with surgical precision.”

Why This Matters

• Antibiotic resistance is one of the biggest threats to global health, with superbugs killing over a million people annually.
• Phage therapy, which uses viruses to kill bacteria, has long been seen as a promising alternative—but finding the right phage is slow and unpredictable.
• AI could dramatically speed up the discovery and design of targeted phages, potentially enabling personalized treatments for infections.

The Ethical Frontier

While the study focused solely on bacteriophages and excluded viruses that infect humans, the implications are profound. Experts warn that AI-designed viruses could behave unpredictably in complex ecosystems. There are also concerns about biosecurity and the potential misuse of such technology.

“We need robust oversight and ethical frameworks,” said a bioethicist not involved in the study. “This is powerful tech, and with great power comes great responsibility.”

What’s Next?

• The team plans to expand Evo’s capabilities to design phages for other bacterial strains, including those responsible for hospital-acquired infections.
• There’s growing interest in using AI to design viruses for agriculture, microbiome engineering, and environmental cleanup.

This breakthrough isn’t just about killing bacteria—it’s about reimagining what life can be. With AI as a co-creator, biology may no longer be bound by the slow march of evolution. It’s entering the age of intelligent design.

Dectrocel Bags ₹4 Crore from BioAngels, PadUp Ventures to Accelerate AI-Powered Healthcare Tools

Dectrocel, a pioneering health-tech company developing AI-powered diagnostic solutions, has raised ₹4 crore in recent funding. The round was led by IAN Group-powered BioAngels, with participation from PadUp Ventures and Vinners.

Key investors from IAN in this round include Nitin Zamre, Samir Kalia, and Mitesh Shah. The fresh infusion of capital will be used to scale Dectrocel’s commercial operations across India, enhance its self-learning foundational multimodal AI technology, expand into international markets, and accelerate the launch of its upcoming AI Tools in CT /MRI/PET-CT and HPB diagnostic modules.

Headquartered in Lucknow, Uttar Pradesh, Dectrocel has launched its flagship product, DecXpert, which is one of only three AI-based diagnostic tools approved by the Central Drugs Standard Control Organization (CDSCO) for clinical use in India. The platform delivers chest X-ray and CT-scan interpretations that are 10 times faster and 98% accurate, addressing India’s acute radiologist shortage - currently at a staggering 1:125,000 doctor-to-patient ratio. This shortage results in diagnosis delays of 7 to 10 days and error rates of up to 40%, particularly in tier-2 and smaller cities where timely intervention can be life-saving.

Dectrocel was founded by Ankit Shukla, an AI-in-medicine expert from the University of Queensland; MS in Infectious Diseases from Duke Medical School, NUS, Singapore. Saumya Shukla, a Doctorate in Public Health from SGPGIMS with an MBA from NUS and MS in Data Science from Harvard; and Nikhil Mishra, an IIT Kanpur Researcher specializing in AI and machine learning applications in medicine.

The company’s mission stems from a deeply personal experience where a patient with a persistent cough went undiagnosed for months due to delayed X-ray interpretations and ultimately succumbed to late-stage lung cancer. This tragedy transformed the founders’ vision into a life-saving mission to democratize access to expert-level diagnostic capabilities for every patient, regardless of geography or income.

Mixed Reality Saves Mobility: Bengaluru Surgeons Rewire Hope in Rare Spine-Brain Procedure

In a case that truly showcased the technological advancements achieved by Bangalore, India in the field of Neuroscience, Niyati (name changed), a 37-year-old young IT Professional from Bengaluru working at US decided to head home for a complex surgery at the junction on base of the skull and upper part of the spine. She was Quadriparetic, which made her bedridden with complete loss of the ability to walk, use her hands or even control urination. When she consulted the neurosurgical center at the US, she was informed that due to the complexity of the surgery she might end up permanently weak in all four limbs and might even need ventilator support for breathing. This had shattered her self-confidence and increased the burden on her family.

6 months before, she noticed the first symptoms, which started with numbness in the limbs and muscle weakness that eventually progressed to quadriparesis. She was diagnosed with Atlantoaxial Dislocation after she moved to India for her treatment, which is basically loss of stability between the two topmost bones of the vertebrae. This condition usually arises due to a congenital deformity, which leads to the compression of the spinal cord that in turn results in neurological problems - culminating into quadriparesis in her case.

Since both bones are placed in a very complicated position, extremely close to the brain stem, it was imperative to gain a clear idea of where and how to operate. The treatment of such complex disorders requires expertise and technology. Technology played a very significant role at this juncture by providing the doctors with clear images that enabled them to plan the surgery in detail. In one-of-its kind situation, the surgical team at Aster Whitfield Hospital utilized Mixed Reality (Augmented Reality + Virtual Reality) to precisely measure the severity of the compression of the brain stem and spinal cord junction, identified bony compressive elements and to locate the vertebral artery in relation to the bones, understand the anatomy of dislocated bone and also rehearse the surgery first.

Mixed Reality (MR), which blends Augmented and Virtual Reality, provides 3D, immersive visualization of the spine with much greater depth perception and spatial awareness than traditional 2D imaging. It enables physicians to examine complex spinal anatomy, plan operations with precision, and diagnose deformities, fractures, and tumors more accurately. Going beyond assisting surgeons, MR also assists patients and families in understanding complicated conditions and procedures better, decreasing fear and enabling informed decision-making.

“Mixed Reality (Augmented Reality + Virtual Reality) greatly helped us to identify the exact position of the arteries to operate on. It also enabled us to anticipate any problems or complications we might face on the table and to prepare for it better.”, said Dr. Ramachandran G, Consultant – Spine & Deformity Surgeon, Aster Whitefield Hospital, Bengaluru. “It provided clear images of the spinal structures that improved our precision and led to a successful outcome.”

The surgery went on for 5 hours which included repositioning of the displaced bones carefully to achieve normal alignment and stability of the spine along with releasing the contracted tissues surrounding the brainstem and vertebral artery that had compressed or tightened. This allowed for better circulation and a reduction in the risk of neurological disorders as well. However, the procedure presented several challenges. Mid-operation bleeding was meticulously managed by the doctors, while neural damage was mitigated through intraoperative neuromonitoring. The surgical team headed by Prof. Dr Satish Rudrappa, Group Director – Aster International Institute of Neurosciences and Spine Care and Dr Ramachandran Govindasamy, Consultant – Spine & Deformity Surgeon at Aster Whitefield Hospital.

“The surgical screws were fed in to intraoperative navigation and the screw trajectories were guided by us to achieve precision. In addition to helping us, Mixed Reality (Augmented Reality + Virtual Reality) assisted the patient and her family to understand the condition as well. It made understanding the problem and surgical procedure easier through holographic imaging which made them trust the process and agree to the surgery faster. This innovative approach allowed for precise navigation and execution of the surgery, leading to a successful outcome.”, said Prof. Dr. Satish Rudrappa, Group Director – Aster International Institute of Neurosciences and Spine Care, Aster Whitefield Hospital, Bengaluru.

Microsurgery, constant intraoperative neurological monitoring and precise postoperative care enabled the patient to attain good neurorehabilitation and be up by the very next day. She could even walk back home in less than 10 days from the surgery. Niyati has resumed her life in the U.S with no further complications. Her story is a testament of how cutting-edge technology and medical advancements can transform lives as well as establish India as a leader in the healthcare industry.

World's 1st FDA Approved Bioelectronic Implant for Arthritis

In a groundbreaking move, the U.S. FDA has approved the SetPoint System, the first neuroimmune modulation implant designed to treat moderate to severe rheumatoid arthritis (RA)—especially for patients who haven’t responded well to traditional medications.

What It Is

• A vitamin-sized neurostimulator implanted in the neck via a minimally invasive outpatient procedure.
• Delivers 1-minute daily electrical pulses to the vagus nerve, which helps regulate inflammation and immune response.
• Patients recharge it wirelessly once a week using a collar-like neckband.

Clinical Impact

Based on the RESET-RA trial (242 patients), the device showed:

• Significant improvement in RA symptoms within 3 months.
• Sustained benefits at 12 months.
• 75% of participants were able to stop other RA medications entirely.
• Reported serious adverse events were low (~1.7%).

Why It Matters

• RA affects over 1.5 million Americans, causing chronic pain, joint damage, and disability.
• Traditional treatments like DMARDs and biologics can be costly and lose effectiveness over time.
• This implant offers a non-pharmaceutical, long-term solution—potentially lasting up to 10 years.

Bioelectronic Medicine Milestone

This marks a major leap in bioelectronic medicine, using the body’s own neural circuits to combat disease. SetPoint Medical plans a targeted U.S. rollout in late 2025, with broader availability expected in 2026.

The results of the RESET-RA study, which led to the FDA approval, are published in the journal Bioelectronic Medicine.

GenAI Healthtech Startup Arintra Raises $21 Mn to Expand Autonomous Coding Platform

• Healthcare organizations are facing increasing financial strain, but current coding solutions are falling short
• Arintra helps providers secure full, compliant reimbursement by combining GenAI-native coding automation, provider-specific clinical documentation improvement (CDI), and payer-aware denials insights while reducing costs
• With proven enterprise-scale outcomes at large health systems and physician groups, and investment from customers such as Endeavor Health Ventures, Arintra continues to expand nationwide

Arintra, the leading GenAI-native autonomous medical coding platform for healthcare providers, today announced $21 million in Series A funding. The round was led by Peak XV Partners, with participation from Endeavor Health Ventures, Y Combinator, Counterpart Ventures, Spider Capital, Ten13, and other strategic investors. The investment will fuel Arintra’s growth as it expands adoption across health systems and physician groups nationwide. The company will accelerate product development, scale its team, and open a new Bay Area headquarters to meet rising demand.

Healthcare organizations are facing greater financial strain than ever. Margins are thinner, coders are in short supply, and payer requirements are becoming increasingly complex. With new policies further impacting insurance reimbursement, providers need proactive automation solutions to get ahead and stay ahead.

Traditional autonomous coding solutions stop at accurately coding charts for reimbursement. Arintra goes further by delivering Revenue Assurance: a proactive, outcomes-driven approach that ensures health systems are reimbursed accurately and efficiently for the care they provide. The result: maximum compliant reimbursement, a more streamlined revenue cycle, with lower costs and tangible ROI.

“At Arintra, we bring together autonomous medical coding, clinical documentation improvement, and denial prevention in a single platform,” said Preeti Bhargava, Co-founder and CTO of Arintra. “By helping providers document what was done, code what was documented, and properly support what was charged, we enable them to secure full, compliant reimbursement at a lower cost, with fewer delays and significantly less manual effort.”

Arintra’s reimagined approach to medical coding has already processed over a billion dollars in healthcare charges. It has helped customers recover millions of dollars in otherwise missed revenue, while reducing manual work and accelerating cash flow.

• At Mercyhealth, Arintra delivered a 5.1% increase in revenue and 43% reduction in denials on claims automated, cut work queue aging by 50%, and lowered coding costs by 32%. Read the full case study.
• At Reid Health, Arintra helped speed up accounts receivable and improve coding accuracy across specialties.

“We chose Arintra because it integrates deeply with Epic and changed how we code without disrupting our workflows. We went from billing delays and high denials to faster A/R and fully automated charge capture. It is one of the few AI tools that delivers hard ROI, fast,” said Muhammad Siddiqui, Chief Information Officer at Reid Health.

The idea for Arintra was drawn from personal experience. After an emergency department visit, co-founder Preeti Bhargava received a surprisingly large bill. Unsure of what to do, she went through months of back-and-forth between her insurer and provider before it was revealed that a simple coding error had caused the issue. This highlighted not only the widespread breakdowns in how care is documented and reimbursed, but it showed how exposed patients and healthcare organizations are to something so technical and obscure that it can be difficult for humans to step in to rectify the issue.

This inspired computer science PhDs Preeti and Nitesh to analyze the problem through a modern technical lens and to reimagine medical coding as a strategic lever for healthcare’s financial health.

“Reimbursement in healthcare is fundamentally broken. Payers are moving fast, using policy and technology to shift more burden onto providers, but autonomous coding hasn't kept up,” said Nitesh Shroff, Co-founder and CEO of Arintra. “We built Arintra to help healthcare providers secure compliant revenue at scale while easing the burden on frontline teams.”

“The disruption of the $150 billion healthcare reimbursements industry will be one of AI’s defining impacts. Arintra’s autonomous system tackles one of the hardest challenges for providers; translating clinical documentation into accurate insurance codes so they get paid fairly and fast. The results speak for themselves; providers are recovering millions in lost revenue by partnering with Arintra. It is a great example of vertical AI done right - real enterprise adoption, clear ROI, and an ambitious roadmap as models continue to improve.” Mohit Bhatnagar, MD, Peak XV. “After backing Nitesh and Preeti at seed through our Surge Program, Peak XV Partners is excited to double down and lead Arintra’s Series A round.”

Arintra’s GenAI native platform combines large language models with clinical knowledge graphs to interpret patient charts in context and apply specialty-specific coding guidelines with precision. Every code that Arintra generates is fully explainable and auditable, helping build trust in a high-stakes environment. The platform integrates natively with leading Electronic Health Record systems (EHRs) including Epic and Athena, operating almost invisibly within existing workflows.

As adoption grows, Arintra continues to expand its capabilities to help more healthcare organizations achieve sustainable financial outcomes. With measurable ROI, lasting customer impact, and a deep understanding of healthcare’s financial challenges, Arintra is poised to become the trusted partner for revenue assurance in healthcare.

Visit https://arintra.com to learn more.

About Arintra

Arintra provides the industry’s leading GenAI-native autonomous coding platform, enabling health systems to get paid accurately and efficiently for the care they deliver, driving revenue assurance at scale. By combining cutting-edge AI with deep clinical expertise, Arintra autonomously codes charts with high accuracy, without human intervention. Unlike bolt-on tools, Arintra works directly within the EHR, ensuring seamless adoption with zero workflow changes or data integrity risk. Health systems use Arintra to unlock missed revenue due to coding gaps, documentation issues, and unchallenged denials - achieving 5%+ uplift in revenue, 12%+ reduction in A/R days, and 43%+ fewer denials.

* Epic is a trademark of Epic Systems Corporation

UST and ThinkBio.Ai Forge Strategic Alliance to Accelerate AI-Driven Innovation in Biopharma and Healthcare

UST, a leading digital transformation solutions company, has partnered with ThinkBio.Ai®, an AI-powered solutions provider for biopharmaceutical and healthcare organizations. This strategic partnership will empower UST to more efficiently leverage its expertise in digital transformation and advanced solutions to complement ThinkBio.Ai’s innovative AI-powered R&D capabilities. Together, the companies will deliver transformative solutions that accelerate AI transformation journeys and improve outcomes for biopharma and healthcare organizations worldwide.

Leveraging advanced in-house expertise in oncology, immunology, neurology, and cardiology, ThinkBio.Ai has developed a suite of AI-powered solutions to address critical challenges across pharma and biotech preclinical and clinical R&D pipelines. These include data-driven strategies to identify the most optimal treatments, salvaging failed drugs through repurposing or combination therapies, and improving clinical trial success through biomarker-driven patient stratification and digital twin-enabled trial matching.

In addition, ThinkBio.Ai’s AI-enhanced Research Co-pilot (R-COP™) utilizes AI to extend the existing Laboratory Information Management System (LIMS) capabilities. Fully interoperable with existing infrastructure, this next-generation tool transforms routine processes into dynamic, insight-driven research operations. These solutions are designed to support biopharma companies and healthcare providers in accelerating innovation and improving patient care.

ThinkBio.Ai’s biological and clinical insights are powered by experts and delivered through the BioThinkHub™ data platform, drawing from expertly curated data and knowledge from proprietary and public data sources.

“This partnership will bring our unique AI and knowledge-based transformation products and solutions for Research and Discovery (R&D) to UST’s focus on digital transformation capabilities and building Gen AI solutions for different industries, including the life science sector. Together, we will build custom ecosystems to help clients and partners stay ahead in a well-regulated, dynamic, and competitive landscape,” said Pradeep Palazhi, Founder and Chief Executive Officer, ThinkBio.Ai®.

“We will integrate ThinkBio.Ai’s AI-powered R&D transformation solutions with UST’s strengths in digital transformation and Gen AI across life sciences – pharma, biotech, and medical devices. This strategic collaboration will drive innovation, accelerate time-to-value, and deliver measurable impact across the research and development value chain for our customers,” said Anu Koshy, Life Science cluster leader, UST.

From Genes to Genius: India Launches Landmark Health Biobank

The Phenome India National Biobank, inaugurated by Union Minister Dr. Jitendra Singh at the CSIR-Institute of Genomics and Integrative Biology (IGIB) in New Delhi, is a state-of-the-art facility designed to collect and store genomic, lifestyle, and clinical data from 10,000 individuals across India.

This initiative captures India's vast diversity—geographically, ethnically, and socio-economically—and is modeled after global benchmarks like the UK Biobank.

Why It Matters

• Decode complex diseases like diabetes, cancer, cardiovascular conditions, and rare genetic disorders
• Enable early diagnosis and targeted therapies
• Support AI-driven diagnostics and gene-guided treatments
• Track long-term health trajectories and gene-environment interactions

Scientific and Societal Impact

• Addresses India-specific health challenges such as central obesity in lean individuals
• Enables population-specific health strategies
• Bridges the gap between lab research and real-world application
• Supports India’s leadership in CRISPR, quantum tech, and antimicrobial resistance research

Core Technologies Powering the Biobank

Technology	Purpose	Application
Genomic Sequencing	Decoding individual DNA	Identifies genetic variants linked to diseases like cancer, diabetes, and rare disorders
CRISPR-based Genome Editing	Functional genomics and therapeutic research	Enables gene-function studies and potential gene therapies for conditions like sickle cell anemia
AI & Machine Learning	Pattern recognition and predictive modeling	Powers diagnostics, risk stratification, and personalized treatment recommendations
Big Data Analytics	Integration of multi-modal datasets	Analyzes genomic, clinical, and lifestyle data across 10,000+ individuals
Digital Health Platforms	Real-time data collection and monitoring	Supports longitudinal tracking of health outcomes and lifestyle factors
Biobanking Infrastructure	Secure sample storage and retrieval	Preserves biological specimens (blood, tissue, etc.) under controlled conditions for future research

Research Focus Areas

• Gene-environment interactions
• Population-specific health strategies
• AI-driven diagnostics
• Drug development and antimicrobial resistance

Strategic Integration

• Complementing India’s broader scientific ecosystem
• Leveraging quantum computing for high-throughput data processing
• Collaborating with CSIR, DBT, and industry for translational research
• Implementing ethical frameworks for data governance and privacy

The Phenome India Biobank is not just a data repository—it is a national health intelligence engine poised to transform healthcare and biomedical research in India.

AI-Powered Eye Scan Slashes Diagnosis Time from Weeks to Seconds!

Taiwan-based Acer Medical’s artificial intelligence-assisted diagnostic software and a combination of Intel hardware- and software-based technology, is making eye lesion detection dramatically faster, said Acer Medical, a subsidiary of Acer group in an official blog post.

Traditionally, diagnosing conditions like diabetic retinopathy or age-related macular degeneration could take weeks, especially when multiple specialists were involved. Now, thanks to Acer Medical’s AI-assisted diagnostic software running on Intel-backed AI PCs, results can be delivered in seconds.

The system uses high-resolution fundus photography to scan the inner eye, with AI algorithms analyzing images instantly. This eliminates the need for dilation-related eye drops and long wait times. The AI PC processes everything locally, meaning no internet connection is required—making it ideal for remote healthcare.

 

Dr. Hsieh Yi-Ting (foreground) demonstrates detailed eye scans of a patient on his Acer Travelmate Spin P4 AI PC, connected to a high-resolution fundus camera. Thanks to AI algorithms developed using Intel OpenVINO tool kits, the medical team sees results in just 10 seconds. (Image Credit: Intel Corporation)

Results are processed using Acer Medical’s VeriSee DR for diabetic retinopathy and VeriSee Age-related Macular Degeneration (VeriSee AMD) for age-related macular degeneration.

Created by Acer Medical in partnership with medical specialists, the technology is available in 13 countries.

Dr. Hsieh Yi-Ting, a retina specialist at National Taiwan University Hospital, developed the VeriSee DR and VeriSee AMD solutions, which are now available in 13 countries. These tools help doctors prioritize cases and expedite treatment, but they don’t replace medical professionals—rather, they enhance their ability to provide faster, more accurate care.

Acer Medical is a subsidiary of the Acer Group specializing in AI-driven medical diagnostics. They focus on leveraging artificial intelligence, clinical data, and software development to create healthcare solutions. The company's technology has been implemented in over 300 hospitals and clinics, serving an estimated 450,000 patients annually.

Their AI-powered tools, like VeriSee DR and VeriSee AMD, help detect eye diseases such as diabetic retinopathy and age-related macular degeneration in seconds, significantly reducing diagnosis time.

 
This AI-driven approach is a game-changer for rural healthcare, allowing specialists to diagnose patients far from hospitals. What do you think about AI’s expanding role in medicine? Do comment your opinion below...

ECOSEP and Tata Elxsi Announce Strategic Partnership to Transform Sports Medicine through AI

European College of Sport and Exercise Physicians (ECOSEP) and Tata Elxsi have announced a strategic partnership that aims to revolutionise the field of sports and exercise medicine through combining the research excellence and clinical expertise of ECOSEP with Tata Elxsi’s AI- and machine learning–driven healthcare solutions and technology capabilities.

The partnership will focus on applying artificial intelligence technologies in areas such as advanced diagnostic tools, personalised treatment plans, predictive analytics for injury prevention, and real-time monitoring of athletes' physical conditions.

This innovative collaboration was initiated by Dr. Pakravan, Vice Chair of ECOSEP, and facilitated by Dr. Malliaropoulos, General Secretary. Speaking on behalf of ECOSEP, Prof. Nicola Maffulli, President, stated: “These are exciting times for how technology and medical science can be brought together to transform personalised care in sports. The long-term vision of Tata Elxsi marries with the aim of ECOSEP to develop and maintain 360° care for athletes and physically active individuals. With the power of Tata Elxsi, ECOSEP shall develop comprehensive packages of care which will help to optimise performance and health. This is a unique opportunity for mutual collaboration, marrying disciplines only apparently different, and allowing close interaction of professionals.”

Anup SS, Practice Head – AI and Machine Learning at Tata Elxsi, added: “This collaboration with ECOSEP represents an exciting opportunity to apply AI in ways that directly impact athlete health and performance. By combining clinical insight with advanced data science, we aim to co-create intelligent tools that support early diagnosis, enable real-time decision-making, and personalise care for every athlete. Together, we’re paving the way for a new era in sports medicine—one that is smarter, faster, and more human-centric.”

The collaboration serves as a stepping stone for future interdisciplinary partnerships aimed at expanding the use of AI in sports and musculoskeletal medicine, and both organisations are committed to advancing the field through research, clinical trials, and the development of AI-driven tools that offer athletes and healthcare providers ground-breaking solutions to achieve optimal outcomes.

Tata Elxsi will join the 9th ECOSEP Congress in Düsseldorf in November 2025 to engage with the clinical community, share early insights, and explore opportunities for collaborative research and innovation.

66% HealthTech Leaders Say Their Organizations Generating Business Value From Several Ai Use Cases :KPMG Report

KPMG has unveiled a new report titled “KPMG Global Tech Report: Healthcare Insights” to better understand how healthcare organizations are navigating the complexities of digital transformation, targeting their technology investments, and deriving value.

By examining the perspectives of 122 healthcare technology leaders from around the world (based on a comprehensive survey of 2,450 global technology leaders including chief digital officers, CIOs, CTOs, CISOs, chief AI officers and other executives) the report provides valuable insights into how healthcare systems and organizations are on the precipice of a technology revolution, and are leveraging advanced technologies and tools to streamline operations, reduce costs and, above all, enhance patient experiences.

“Today healthcare technology leaders believe robust regulatory frameworks are a must to ensure the safety and privacy of data in cloud-hosted solutions. They believe this assurance enables them to advance technological innovation with confidence. Prioritizing comprehensive data interoperability frameworks is critical for seamless communication between systems across organizations and jurisdictions. Such connectivity can drive accurate patient care, promote global collaboration in medical research, and strengthen AI model training through access to diverse datasets.” said Lalit Mistry Partner and Co-head, Healthcare Sector, KPMG in India.

Key Findings from the Report:

• 70 per cent of healthcare respondents are satisfied with the amount of value they are getting from their technology investments.
• Compared with a year ago, more healthcare organizations are developing and testing data and analytics strategies or already have a strategic vision for their capabilities
• 70 per cent say cyber security teams are typically involved in the earliest planning stages and have a high degree of influence when it comes to tech investment decision-making
• 66 per cent of healthcare technology leaders say their organizations are generating business value from several AI use cases
• 61 per cent of healthcare technology leaders are currently prioritising AI and Automation as they consider how to invest in technology to support their ambitions.
• 57 per cent admit that flaws in their organizations’ enterprise IT systems disrupt business as usual on a weekly basis.
• Top 3 factors slowing down digital transformation in healthcare includes – Cyber security and privacy concerns, transformation fatigue and immature data management strategies. 
• Healthcare leads all other sectors when it comes to prioritizing and investing in Web3 technology including blockchain and tokenization.

Dehradun HealthTech Startup Caught Attention & Praise of Bill Gates and Other Global Leaders

Indian health-tech startup Sunfox has caught the attention of global leaders, earning praise from Bill Gates

At the Indian Council of Medical Research (ICMR) headquarters, Sunfox Technologies was showcased as one of the five breakthrough healthcare technologies selected for its potential to transform global health. The event, which brought together some of India's most impactful medical innovations, was further marked by the presence of renowned philanthropist and Microsoft co-founder Bill Gates.

Spandan, a pioneering technology in cardiac monitoring, stood out for its ability to make hospital-grade cardiac care accessible and affordable. In a one-on-one conversation with Bill Gates, Spandan’s impact on reducing cardiac mortality worldwide was acknowledged and praised.

Reflecting on the experience, Rajat Jain, Founder of Sunfox Technologies, stated, “Being at ICMR HQ among India’s most promising healthcare innovations was an incredible honor. Hearing Bill Gates recognize Sunfox Technologies’s potential to change the world was both humbling and energizing. It reinforced our mission to make high-quality cardiac monitoring accessible to millions."

Bill Gates, impressed by the innovation, emphasized the broader impact of India's healthcare advancements, stating:

At Indian Council of Medical Research (ICMR), I saw how India’s homegrown innovations are saving lives. Fetal monitoring systems are helping mothers and newborns, real-time TB detection is catching cases sooner, and streamlined delivery systems are bringing medicine to remote communities faster. These breakthroughs aren’t just changing health outcomes in India—they have the power to change the world.

At @ICMRDELHI, our chair @BillGates learned about homegrown innovations that are addressing India’s healthcare needs, and have the potential to solve global health challenges.
We remain committed to partnering with the Government of India to support domestic innovations to solve… pic.twitter.com/l3RuRzB2x1

— Gates Foundation India (@BMGFIndia) March 20, 2025

Heart disease remains one of the leading causes of death globally, and Sunfox Technologies is poised to address this challenge by placing life-saving technology into the hands of millions. With its innovative approach to affordable, real-time cardiac monitoring, Sunfox Technologies has the power to significantly reduce cardiac-related fatalities and improve healthcare accessibility worldwide.

About Sunfox Technologies:

Sunfox Technologies, founded in 2016 and based in Dehradun, is a leading med-tech company focused on making healthcare accessible and affordable. Specializing in biomedical instrumentation, AI, and IoT-based solutions, its flagship innovation, Spandan, is a portable ECG device that detects over 40 heart abnormalities with 99.7% accuracy. Recognized by the Prime Minister of India and featured on Shark Tank India, Sunfox has impacted thousands of lives by improving cardiac care. With a vision to serve the next billion, the company continues to develop cutting-edge, life-saving medical solutions to bridge healthcare gaps in underserved communities worldwide.

Website: https://sunfox.in/

LinkedIn: https://www.linkedin.com/company/sunfox/